Management of Anticoagulants in the Periprocedural Period for Patients With Cancer

Authors:
Anita Pudusseri From North Shore-LIJ Health System at Lenox Hill Hospital and Hofstra North Shore-LIJ School of Medicine, New York, New York.

Search for other papers by Anita Pudusseri in
Current site
Google Scholar
PubMed Close
 DO
and
Alex C. Spyropoulos From North Shore-LIJ Health System at Lenox Hill Hospital and Hofstra North Shore-LIJ School of Medicine, New York, New York.
From North Shore-LIJ Health System at Lenox Hill Hospital and Hofstra North Shore-LIJ School of Medicine, New York, New York.

Search for other papers by Alex C. Spyropoulos in
Current site
Google Scholar
PubMed Close
 MD, FRCPC
Volume/Issue:
Volume 12: Issue 12
Online Publication Date:
Dec 2014
DOI:
https://doi.org/10.6004/jnccn.2014.0173
Restricted access

Patients with cancer undergo surgeries and procedures for various purposes, including prophylaxis, diagnosis, staging, cure, debulking, palliation, and reconstruction. The diagnosis of cancer itself, along with the well-established complication of venous thromboembolism (VTE), places these patients at risk for perioperative thromboembolism. It is also well-established that continuing patients on oral anticoagulation therapy during the periprocedural period is associated with an increased risk of bleeding. Rates of periprocedural VTE and major bleeding are significantly higher in patients with cancer, presenting a complex problem for clinicians in terms of periprocedural anticoagulation management. This article reviews the current recommendations regarding periprocedural anticoagulation management in patients with cancer.

Correspondence: Anita Pudusseri, DO, North Shore-LIJ Health System at Lenox Hill Hospital, 100 East 77th Street, New York, NY 10065. E-mail: apudusseri@nshs.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1

    Howlader N, Noone AM, Krapcho M et al., eds. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Accessed November 10, 2014.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Rosenberg SA. Surgical oncology: general issues. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer Principles & Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:268–276.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Douketis JD, Foster GA, Crowther MA et al.. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160:3431–3436.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Caliendo FJ, Halpern VJ, Marini CP et al.. Warfarin anticoagulation in the perioperative period: is it safe? Ann Vasc Surg 1999;13:11–16.

  • 5

    Tafur AJ, Wysokinski WE, McBane R et al.. Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Onc 2012;23:1998–2005.

  • 6

    Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162–1173.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Weibert RT. Oral anticoagulant therapy in patients undergoing dental surgery. Clin Pharm 1992;11:857–864.

  • 8

    Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120:2954–2962.

  • 9

    Ansell J, Hirsh J, Hylek E et al.; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th ed). Chest 2012;133(Suppl 6):160S–198S

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 1996;30:300–313.

  • 11

    Kovacs MJ, Kearon C, Rodger M et al.. Single-arm study of bridging therapy with low-molecular weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110:1658–1663.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R et al.. Long-term use of different doses of low-molecular weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism. Ann Vasc Surg 2010;24:628–639.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Schmid P, Brodmann D, Odermatt Y et al.. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost 2009;7:1629–1632.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Kaatz S, Koudes PA, Garcia DA et al.. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87(Suppl 1):S141–145.

  • 15

    Levine MN, Gu C, Liebman HA et al.. A randomized phase II trial of apixiban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012;10:807–814.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Morimoto Y, Niwa H, Minematsu K. Hemostatic management of tooth extractions in patients on oral antithrombotic therapy. J Oral Maxillofac Surg 2008;66:51–57.

  • 17

    Carter G, Goss A. Tranexamic acid mouthwash-a prospective randomized study of a 2-day regimen vs. 5-day regimen to prevent postoperative bleeding in anticoagulated patients requiring dental extractions. Int J Oral Maxillofac Surg 2003;32:504–507.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Kargi E, Babuccu O, Hosnuter M et al.. Complications of minor cutaneous surgery in patients under anticoagulant treatment. Aesthetic Plast Surg 2002;26:483–485.

  • 19

    Lip JY, Durrani OM, Roldan V et al.. Perioperative management of ophthalmic patients taking antithrombotic therapy. Int J Clin Pract 2011;65:361–371.

  • 20

    Liu S, Carpenter RL, Neal JM. Epidural anesthesia and analgesia. Their role in postoperative outcome. Anesthesiology 1995;82:1474–1506.

  • 21

    Rodgers A, Walker N, Schug S et al.. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomized trials. BMJ 2000;321:1493.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Horlocker TT, Wedel DJ, Rowlingson JC et al.. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy. Reg Anesth Pain Med 2010;35:64–101.

  • 23

    Hylek EM, Regan S, Go AS et al.. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001:135:393–400.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Marietta M, Bertesi M, Simoni L et al.. A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery. Clin Lab Haematol 2003;25:127–130.

  • 25

    Douketis JD, Johnson JA, Trupie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319–1326.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26

    Dunn A. Perioperative management of oral anticoagulation: when and how to bridge. J Thromb Thrombolysis 2006;21:85–89.

  • 27

    Spyropoulos AC, Turpie AG, Dunn AS et al.; REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006;4:1246–1252.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28

    Geerts WH, Bergquvist D, Pineo GF et al.. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):381S–453S.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Hirsh J, Raschke R. Heparin and low-molecular weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):188S–203S.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Strebel N, Prins M, Agnelli G et al.. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002;162:1451–1456.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31

    Turpie AG, Bauer KA, Eriksson BI et al.. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833–1840.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    van Ryn J, Stangier J, Haertter S et al.. Dabigatran etexilate- a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116–1127.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33

    Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012;119:3016–3023.

  • 34

    Stangier J, Rathgen K, Stahle H et al.. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-center study. Clin Phmaracokinet 2010;49:259–268.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    Rahbavan N, Frost CE, Yu Z et al.. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74–81.

Copyright:
Copyright © 2014 by the National Comprehensive Cancer Network 2014
Page Numbers:
8
Article Category:
Research Article
Received:
13 Apr 2014
Accepted:
05 Aug 2014
Print Publication Date:
01 Dec 2014
Online Publication Date:
Dec 2014

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1704 592 49
PDF Downloads 488 47 0
EPUB Downloads 0 0 0